Why Your Marketing Team Is Creating Clinical Evaluation Risk

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

This is not an unusual situation. It happens in every company at every stage of maturity. Marketing develops content that sounds reasonable, commercial teams refine it to sound compelling, and then someone remembers that clinical evaluation might have an opinion about it.

By that point, launch timelines are locked, materials are designed, and sales training is scheduled. The expectation is that clinical will rubber-stamp the content and move on.

But MDR Article 7 does not operate on launch timelines.

The Regulatory Framework Nobody Wants to Read

Article 7 is titled

Where Marketing Claims Cross the Regulatory Line

Under EU MDR Article 7, clinical claims made in promotional materials must be substantiated by clinical evidence included in the Clinical Evaluation Report (CER). If your marketing team promotes a clinical benefit that is not supported by your clinical data, the Notified Body may issue a major non-conformity. This applies to website copy, brochures, trade show materials, and even social media posts.

Common violations include overstating device performance, using superlatives like “most effective” without comparative clinical data, and referencing clinical outcomes from non-equivalent devices. Regulatory authorities increasingly cross-reference marketing materials against technical documentation during market surveillance.

Building a Compliant Claims Management Process

Every clinical claim should go through a validation workflow before publication. This process should involve:

• A claims matrix linking each marketing statement to specific clinical evidence in the CER
• Regulatory review of all customer-facing materials before publication
• Clear distinction between intended purpose claims (regulated) and general product descriptions
• Regular audits of published marketing materials against the current state of clinical evidence
• Training for marketing teams on MDR Article 7 requirements and the consequences of non-compliance

Remember that MDR holds the manufacturer responsible for all claims made about the device, regardless of which department created them. A structured claims management process protects both the CE marking and the company from regulatory enforcement actions.

Real-World Examples of Marketing-Driven Regulatory Issues

Market surveillance authorities across Europe have increasingly focused on the alignment between marketing claims and clinical evidence. In 2024, several manufacturers received corrective action requests after their promotional websites made performance claims that exceeded the clinical data in their technical files. These cases resulted in forced website modifications, product recalls, and in some instances, suspension of CE certificates.

One common scenario involves marketing teams using clinical investigation results selectively, highlighting positive outcomes while omitting limitations or subgroup analyses that showed less favorable results. Under MDR Article 7, this selective presentation constitutes misleading information, even if the cited data is technically accurate.

Another frequent issue arises when marketing materials reference regulatory clearance in other jurisdictions (such as FDA 510(k)) as evidence of clinical performance in the EU. MDR requires independent clinical evaluation based on European standards and the specific intended purpose defined for the EU market. Regulatory approvals from other regions may support the body of evidence but cannot replace the structured clinical evaluation required under Annex XIV.